Mikofenolat Mofetil sebagai Terapi Sindrom Nefrotik Relaps Sering dan Resisten Steroid pada Anak

Sudung O. Pardede

Sari


Abstrak. Sindrom nefrotik relaps sering, sindrom nefrotik dependen steroid, dan sindrom nefrotik resisten
steroid pada anak merupakan sindrom nefrotik yang sulit diobati. Hasil pengobatan dengan imunosupresan
seperti siklofosfamid, klorambusil, levamisol, atau siklosporin-A yang diberikan secara oral maupun intravena
sering kurang memuaskan. Mikofenolat mofetil (MMF) merupakan imunosupresan yang menghambat
enzim inosine monophosphate dehydrogenase, bekerja secara selektif, tidak kompetitif, dan reversibel.
Preparat MMF telah digunakan dalam tata laksana penyakit ginjal. Pada sindrom nefrotik relaps seringdependen
steroid, MMF dapat menyebabkan penurunan mean relapse rate dari 4,1 menjadi 1,3 relaps per
tahun, menyebabkan remisi total dengan perbaikan fungsi ginjal, dan mempertahankan keadaan remisi.
Pada sindrom nefrotik resisten steroid, MMF dapat menyebabkan dan frekuensi perawatan menurun remisi
total dan mengubah keadaan sindrom nefrotik resisten steroid menjadi responsif steroid. Preparat MMF
dapat digunakan sebagai monoterapi atau kombinasi dengan imunosupresan lain pada anak dengan sindrom
nefrotik bermasalah. Terbukti MMF dapat menyebabkan remisi total, mengubah keadaan resisten steroid
menjadi responsif steroid, dan menurunkan kejadian relaps


Kata Kunci


sindrom nefrotik; relaps sering; dependen steroid; resisten steroid; dan mikofenolat mofetil

Teks Lengkap:

PDF

Referensi


Haycock G. The child with idiopathic nephrotic syndrome.

Dalam: Webb N, Postlethwaite RJ, penyunting. Clinical

paediatric nephrology, edisi ke-3. New York; Oxford

University Press; 2003.h.341-66.

Niaudet P. Steroid resistant idiopathic nephrotic

syndrome. Dalam: Avner ED, Harmon WE, Niaudet P.

Pediatric nephrology, edisi ke-5. Philadelphia; Lippincott

Williams & Wilkins; 2004.h.557-74.

Mendizabal S, Zamora I, Berbel O, Sanahuja MJ,

Fuentes J, Simon J. Mycophenolate mofetil in steroid/

cyclosporine-dependent/resistant nephrotic syndrome.

Pediatr Nephrol 2005; 20:14-9.

Consensus statement on management and audit potential

for steroid responsive nephrotic syndrome. Report of

a Workshop by British Association for Paediatric Nephrology

and Research Unit, Royal College of Physicians.

Archs Dis Child 1994; 70:151-7.

Consensus statement on management of steroid sensitive

nephrotic syndrome. Indian Pediatr Nephrol Group, Indian

Academy of Pediatrics. Indian Pediatrics, 2001;38:975-86.

Alatas H, Tambunan T, Trihono, PT, Pardede, SO.

Konsensus tata laksana sindrom nefrotik idiopatik pada

anak. Unit Kerja Koordinasi Nefrologi IDAI, 2005.

Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder

of T-cell function. Lancet 1974; 7:556-9.

Bakker WW, van Luijk WHJ. Do circulating factors play

a role in the pathogenesis of minimal change nephrotic

syndrome? Pediatr Nephrol 1989; 3:341-9.

Allison AC, Eugui EM. Mycophenolate mofetil and its

mechanisms of action. Immunopharmacology 2000;

:85-118.

Briggs A, Choi MJ, Scheel PJ Jr. Successful treatment of

glomerular disease with mycophenolate mofetil. Am J

Kidney Dis 1998; 31:213-7.

Miller G, Zimmerman R, Radhakrishan J, Appel G. Use

of mycophenolate mofetil in resistant membranous

nephropathy. Am J Kidney Dis 2000; 36:250-7.

Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ,

Sothinathan R, dkk. Mycophenolate mofetil treatment

for primary glomerular diseases. Kidney Int 2002;

:1098-114.

Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, Ji

YL. dkk. Efficacy of mycophenolate mofetil in patients

with diffuse proliferative lupus nephritis. N Engl J Med

; 343:1156-62.

Chandra M, Susin M, Abithol C. Remission of relapsing

childhood nephrotic syndrome with mycophenolate

mofetil. Pediatr Nephrol 2000; 14:224-6

Novak I, Frank R, Vento S, Vergara M, Gauthier B,

Trachtman H. Efficacy of mycophenolate mofetil in

pediatric patients with steroid-dependent nephrotic

syndrome. Pediatr Nephrol 2005; 20:1265-8.

Jacqz-Aigrain E, Shaghaghi EK, Baudouin V, Popon M,

Zhang D, Maisin A, dkk. Pharmacokinetics and

tolerance of mycophenolate mofetil in renal transplant

children. Pediatr Nephrol 2000; 14:95-9.

Montane B, Abithol C, Chandar J, Strauss J,

Zilleruolo. Novel therapy of glomerulosclerosis with

mycophenolate and angiotensin blockade. Pediatr

Nephrol 2003; 18:772-7.

Bayazit AK, Bayazit Y, Noyan A,Gonlusen G, Anarat

A. Comparison of mycophenolate mofetil and

azathioprine in obstructive nephropathy. Pediatr

Nephrol 2003; 18:100-4.

Arbeiter K, Greenbaum L, Balzar E, Muller T,

Hofmeister F, Bidmon B, dkk. Reproducible erythroid

aplasia caused by mycophenolate mofetil. Pediatr

Nephrol 2000; 14:195-7.

Briggs A, Choi MJ, Gimenez LF, Scheel PJ Jr. Treatment

of primary glomerulopathies (10GN) with mycophenolate

mofetil (abstrak). Abstract of the ASN 31st Annual Meeting,

Oktober 1998. Philadelphia. 1998: 437

Bunchman T, Navarro M, Broyer M, Sherbotie J,

Chavers B, Tonshoff B, dkk. The use of mycophenolate

mofetil suspension in pediatric renal allograft recipients.

Pediatr Nephrol 2001; 16:978-84.

David-Neto E, Araujo LMP, Sumita NM, Mendes ME,

Castro MCR, Alves CF, dkk. Mycophenolic acid

pharmacokinetics in stable pediatric renal transplantation.

Pediatr Nephrol 2003; 18;266-72.

Filler G, Hansen M, LeBlanc C, Lepage N, Franke D,

Mai I, dkk. Pharmacokinetics of mycophenolate mofetil

for autoimmune disease in children. Pediatr Nephrol

; 18:445-9.

Barletta GM, Smoyer WE, Bunchman TE, Flynn JT,

Kershaw DB. Use of mycophenolate mofetil in steroiddependent

and resistant nephrotic syndrome. Pediatr

Nephrol 2003; 18:833-7.

Gellermann J, Querfeld U. Frequently relapsing

nephrotic syndrome: treatment with mycophenolate

mofetil. Pediatr Nephrol 2004; 19:101-4.

Hogg RJ, Fitzgibbon L, Bruick J, Bunke M, Ault B,

Baqi N, dkk. Clinical trial of mycophenolate mofetil

(MMF) for frequent relapsing nephrotic syndrome in

children. Abstract. Pediatr Nephrol 2004, 19:C66:

OFC18.

Al-Akash SA, Al-Makadma AS. Mycophenolate mofetil

(MMF) is effective in steroid-dependent or frequently

relapsing nephrotic childrens. Abstract. Pediatr Nephrol

, 19:C93: P002.

Okada M, Yagi K, Yanagida H, Kuwajima H, Tabata N,

Sugimoto K, Takemura T. Therapeutic effects of

mycophenolate mofetil (MMF) on multidrug-resistant

intractable nephrotic syndrome. Abstract. Pediatr

Nephrol 2004, 19:C102:P042.

Voznosenskaya T, Sergeeva T, Varshavskiy V, Tsyigin A.

Effect of mycophenolate mofetil in nephrotic children.

Abstract. Pediatr Nephrol 2004, 19:C220:P514.




DOI: http://dx.doi.org/10.14238/sp9.1.2007.23-31

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc-sa4.footer##

Informasi Editorial:
Badan Penerbit Ikatan Dokter Anak Indonesia
Jl. Salemba I No 5, Jakarta 10430, Indonesia
Phone/Fax: +62-21-3912577
Email: editorial [at] saripediatri.org

Lisensi Creative Commons
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.